Drug Trial Radar · NCT07203001
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 3, 2025
Primary completion
Apr 22, 2027
Study completion May 17, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
Conditions
- Still´s Disease
Interventions
MAS825Drug
Experimental drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with clinical response based on one set of response criteriaTime frame: Day 85
Locations
24 sites in 8 countries. Site status is shown where the registry gives one.
Cincinnati Childrens Hospital
Cincinnati, Ohio · Active not recruiting
Legacy Emanuel Research Hosp Portland
Portland, Oregon · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Withdrawn
Novartis Investigative Site
Montreal, Quebec, Canada · Withdrawn
Novartis Investigative Site
Bordeaux, France · Recruiting
Novartis Investigative Site
Bron, France · Recruiting
Novartis Investigative Site
Le Kremlin-Bicêtre, France · Recruiting
Novartis Investigative Site
Lille, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Paris, France · Recruiting
Novartis Investigative Site
Heidelberg, Germany · Recruiting
Novartis Investigative Site
Münster, Germany · Recruiting
Novartis Investigative Site
Sankt Augustin, North Rhine-Westphalia, Germany · Recruiting
Novartis Investigative Site
Florence, FI, Italy · Recruiting
Novartis Investigative Site
Genova, GE, Italy · Recruiting
Novartis Investigative Site
Roma, RM, Italy · Recruiting
Novartis Investigative Site
Utrecht, Netherlands · Active not recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Novartis Investigative Site
Valencia, Spain · Recruiting
Novartis Investigative Site
Esplugues, Barcelona, Spain · Recruiting
Novartis Investigative Site
Istanbul, Fatih, Turkey (Türkiye) · Recruiting
Novartis Investigative Site
Ankara, Sihhiye Altindag, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.